There is a “super sizing” trend in the clinical supply industry as larger vendors continue to acquire their smaller competitors. In the last year alone, there were seven acquisitions that occurred between vendors.
Blistering – a thin film that lets patients “pop” tablets out of a protective cavity – isn’t as common in clinical packaging as it used to be. The rise of biotech means more vials, syringes, and injectables at play in modern trials. Still, blistering is critical to the protection and integrity of many tablet-based clinical studies, and getting it right is key to trial success.
We see a ton of RFPs at Xerimis. At this point in our growth, we know what information a company needs to provide to determine if we’re a good fit for their trial. But RFPs are still a good way for us to get on the same page with a prospect, some of whom don’t have as much experience in the industry.
Choosing the right cold chain system is key to keeping trials on schedule and free of logistical headaches. Xerimis guides clients toward suggested logistical plans and helps you to understand how and why we land there.
Xerimis, Inc. is proud to announce that Tom Brady has been hired as Director of Business Development, North America. Tom will be responsible for working with sponsor companies throughout North America to satisfy their clinical supply needs.
Simon comes to Xerimis with 10 years of direct clinical supply experience and a PhD, Analytical Organic Chemistry. He has extensive experience working for leading pharma companies including Pfizer, Takeda, and Daiichi Sankyo. He has also managed clinical supply projects as a vendor while working with BAP Pharma.